Responses
Regular and young investigator award abstracts
Clinical trials in progress
403 Early results from a phase 1 study to evaluate safety, pharmacokinetics, and efficacy of AMG 404, a programmed death-1 (PD-1) antibody, in patients with advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
